Filing Details

Accession Number:
0000899243-18-018316
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-06-27 16:24:20
Reporting Period:
2018-06-25
Accepted Time:
2018-06-27 16:24:20
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1690585 Magenta Therapeutics Inc. MGTA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1741286 Jason Gardner C/O Magenta Therapeutics, Inc.
50 Hampshire Street
Cambridge MA 02139
See Remarks Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-06-25 25,719 $0.00 292,990 No 4 C Indirect By J.P. Gardner Irrevocable Trust
Common Stock Acquisiton 2018-06-25 21,677 $0.00 359,092 No 4 C Indirect By P.S. Gardner Irrevocable Trust
Common Stock Acquisiton 2018-06-25 400 $15.00 363,212 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect By J.P. Gardner Irrevocable Trust
No 4 C Indirect By P.S. Gardner Irrevocable Trust
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2018-06-25 30,000 $0.00 11,611 $0.00
Common Stock Series A Preferred Stock Disposition 2018-06-25 36,700 $0.00 14,203 $0.00
Common Stock Series B Preferred Stock Disposition 2018-06-25 15,000 $0.00 5,804 $0.00
Common Stock Series B Preferred Stock Disposition 2018-06-25 19,314 $0.00 7,474 $0.00
Common Stock Series C Preferred Stock Disposition 2018-06-25 21,459 $0.00 8,304 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.
  2. Reflects shares that were purchased through a directed share program in connection with the Issuer's initial public offering.